Open Access Open Access  Restricted Access Subscription or Fee Access

Review Study of Overview, Description of Production Details with Mechanism of Action of Corona Vaccines

Chanchal chaurasiya, Mohd Aasim

Abstract


Coronavirus has infected more than 180 countries. Corona virus was most quickly spread from the Wuhan human seafood market (South China). WHO named COVID-19 a worldwide pandemic disease in March 2020 as a consequence of a virus outbreak on the global level, it is transmitted through droplet infection which helps in the quiet spreading of the coronavirus. Several research has been conducted to combat the virus's spread, and vaccine has been approved to be used. The countries from the whole world work with extremely high intentions to introduce vaccine for corona soon with affinity. The countries spend Trillions of expenditures to achieve the purpose. The article aimed to brief the knowledge about the types of corona vaccines, mechanism of action of corona vaccines, an overview of corona vaccines with production details. Mechanism of Action all corona vaccinations have not been thoroughly studied. The goal of this study is to present information about the entire corona vaccination in a single document. Anyone does not need to independently learn about each vaccine's details.

Keywords


Corona vaccines; production; Mechanism of action; mRNA vaccine, Protein subunit vaccine, Inactivated vaccines, Viral vector vaccine.

Full Text:

PDF

References


Yang J, Zheng Y, et al., “Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis”, International Journal Infectious Disease, March 2020, 10(10.1016), DOI: https://doi.org/10.1016/j.ijid.2020.03.017.

Cui J, Li F et al., “Origin and Evolution of pathogenic coronaviruses", Nature Review of Microbiology, 2019, 17(3), 181–92, DOI: 10.1038/s41579-018-0118-9.

Monchatre-Leroy E, Boue F, et al., “Identification of alpha and beta coronavirus in wildlife species in France: Bats, Rodents, Rabbits, and Hedgehogs”, Viruses, 2017, 9(12), 364, DOI: 10.3390/v9120364.

Peng X, Xu X et al., “Transmission routes of 2019-nCoV and controls in dental practice”, International Journal of Oral Sciences, 2020, 12(1), 1–6, https://doi.org/10.1038/s41368-020-0075-9.

Centers for Disease Control and Prevention, “Vaccines and immunization”, https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm.

University of Oxford, Oxford vaccine group, “Vaccine Knowledge Project”, April 30, 2021, https://vk.ovg.ox.ac.uk/vk/types-of-vaccine. 7.U.S. Department of Health and Human Services, “Immunization”, https://www.hhs.gov/immunization/basics/types/index.html.

Kristin Alexander, “Coronavirus Disease 2019 Vaccine Barriers: Educating Patients to Alleviate Fear of Receiving the Vaccine”, The Journal for Nurse Practitioners, 2021, 1075-1077, DOI: 10.1016/j.nurpra.2021.06.019.

John Clemens, Asma Binte Aziz, et al., “Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle-income countries”, The Lancet Journal, December 24, 2021, 101253, https://doi.org/10.1016/j.eclinm.2021.101253.

Seale H, Heywood AE, et al., “Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine”, BMC Infectious Disease, 2021, 21(1), 1–9, https://doi.org/10.1186/s12879-021-05833-1.

Dodd RH, Cvejic E, et al., “Willingness to vaccinate against COVID-19 in Australia”, Lancet Infectious Disease, 2021, 21(3), 318–9, DOI: 10.1016/S1473-3099(20)30559-4.

“Fact sheet: Explaining Operation Warp Speed”, US Department of Health and Human Services, September 22, 2020.

Webb Hooper M, Napoles AM, et al., “No populations left behind: vaccine hesitancy and equitable diffusion of effective COVID-19 vaccines”, Journal of General Internal Medicine, March 22, 2021. https://doi.org/10.1007/s11606- 021-06698-5. 0

Centers for Disease Control and Prevention, “Johnson & Johnson Janssen COVID-19 vaccine overview and safety”, June 1, 2021, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html.

World Health Organization, Vaccines, WHO recommendation Novavax Inc. COVID-19 vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) - NUVAXOVID™: https://extranet.who.int/pqweb/vaccines/who-recommendation-siipl-covid-19-vaccine-rs-proteinnanoparticle.

World Health Organization, Vaccines, WHO recommendation Serum Institute of India Pvt. Ltd. (SIIPL) – COVID-19 vaccine (SARS-CoV-2 rS Protein Nanoparticle [Recombinant]) - COVOVAX™: https://extranet.who.int/pqweb/vaccines/who-recommendation-siipl-covid-19-vaccine-rs-proteinnanoparticle.

World Health Organization, Vaccines, WHO recommendation Moderna COVID-19 mRNA Vaccine (nucleoside modified): https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified.

World Health Organization, Vaccines, WHO recommendation BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY: https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-mrna-vaccine-nucleoside-modified-comirnaty.

World Health Organization, Vaccines, WHO recommendation Bharat Biotech International Ltd – COVID-19 vaccine (Whole Virion Inactivated Corona Virus: https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion.

World Health Organization, Vaccines, WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac: https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac.

World Health Organization, Vaccines, WHO recommendation COVID-19 Vaccine BIBP/Sinopharm: https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp.

World Health Organization, Vaccines, WHO recommendation Janssen–Cilag International NV (Belgium) COVID-19 Vaccine (Ad26.COV2-S [recombinant]: https://extranet.who.int/pqweb/vaccines/who-recommendation-janssen-cilag-international-nv-belgium-covid-19-vaccine-ad26cov2-s. 23.World Health Organization, Vaccines, WHO recommendation Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD™: https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield.

World Health Organization, Vaccines, WHO Recommendation AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant]): https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant.

Centers for Disease Control and Prevention, Understanding How COVID-19 Vaccines Works, February 24, 2022, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html#:~:text=Protein%20subunit%20vaccines%20(vaccines%20under,instead%20of%20the%20entire%20germ.

Gao Fan, An Chaoqiang, et al., “Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine”, Vaccine, DOI: https://doi.org/10.1016/j.vaccine.2022.02.048.

Ewer J. Katie, Barrett R. Jordan et al., “T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial”, LETTERS NATURE MEDICINE, February 2021, 27, 270-78, https://doi.org/10.1038/s41591-020-01194-5.

Suys Estelle J.A, Pilkington Emily H., et al., “From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontier of infectious disease” Acta Biomaterialia, 2021, 131, 16-40, DOI: 10.1016/j.actbio.2021.06.023.

S.N Nagesha, B.N Ramesh, et al., “SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study”, Materials Today: Proceeding, 2022, 49, 904-912, DOI: 10.1016/j.matpr.2021.07.163.

Saleh Ola Ali, Halperin Ofra, et al., “Influenza virus vaccine compliance among pregnant women during the COVID-19 pandemic (pre-vaccine era) in Israel and future intention to uptake BNT162b2 mRNA COVID-19 vaccine”, Vaccine, 2022, 40, 2099-2106, DOI: 10.1016/j.vaccine.2022.02.026.

Ma Chao, Sun Weiwei, et al., “Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vac-cines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021”, Vaccine, March 26, 2022, DOI: https://doi.org/10.1016/j.vaccine.2022.03.067.

Martin Yella Hewings, “COVID-19: How do inactivate vaccines work?”, January 22, 2021, https://www.medicalnewstoday.com/articles/covid-19-how-do-inactivated-vaccines-work.

Zhang Yu, Liu Aijing et l., “An inactivated vaccine based on artificial non-pathogenic fowl adenovirus 4 protects chickens against hepatitis-hydropericardium syndrome”, Veterinary Microbiology, 2022, 264, 0378-1135, https://doi.org/10.1016/j.vetmic.2021.109285.

Wu Liting, Li Lan, et al., “Antimicrobial roles of phagocytosis in teleost fish: Phagocytic B cells vs professional phagocytes”, Aquaculture and Fisheries, December 22, 2021, DOI:https://doi.org/10.1016/j.aaf.2021.12.00.

W. Jonathan, Van Ryzin, “Phagocytic microglia in development: Are they what they eat ?”, Brain, Behavior, & Immunity - Health, December 2021, 18, 100373, DOI: 10.1016/j.bbih.2021.100373.

Custers Jerome, Kim Denny, et al., “Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment”, Vaccine, 2021, 39, 3081-3101, DOI: 10.1016/j.vaccine.2020.09.018.

Barouch DH, Liu J, et al., “Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)” Journal of Infectious Disease 2013, 207(2), 248–56, DOI:10.1093/infdis/jis671. 38.Centers for Disease Control and Prevention, Understanding Viral vector vaccines works, March 14, 2022, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html.




DOI: https://doi.org/10.37591/(rrjops).v14i1.1262

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research and Reviews: A Journal of Pharmaceutical Science